Items tagged with Access
GSK eases intellectual property rights for poorest countries (post)
March 31, 2016 - As the United Nations Secretary General’s High-Level Panel on Access to Medicines initiative continues its work, the GlaxoSmithKline company today announced steps to further help bring innovative medicines to poor countries.
New fixed-dose paediatric TB formulations now available for procurement through the Global Drug Facility (post)
31 March 2016 – Geneva, Switzerland - The new fixed-dose paediatric formulations are now available for procurement through the Global Drug Facility (GDF): rifampicin 75 mg + isoniazid 50 mg + pyrazinamide 150 mg and rifampicin 75 mg + isoniazid 50. The products dissolve in water, have a fruit flavour, and are simple to administer.
UNITAID report considers how to make essential medicines affordable (post)
A new UNITAID study considers how to make essential medicines available and affordable to those in need. Drawing examples from intellectual-property issues in the treatment of HIV, hepatitis C, tuberculosis and cancer, the authors recommend various options that governments can take to lower prices and increase access to essential medicines.
Why India needs to show some spine (post)
In the area of intellectual property, public health and access to medicines, the Narendra Modi government should consider its independence to be of the utmost importance.
The low cost of universal access (post)
TAG talks with Andrew Hill, senior visiting research fellow in the University of Liverpool’s Department of Pharmacology, about his group’s work exploring what it actually costs to profitably mass-produce generic drugs for HIV, viral hepatitis, and cancer. These estimates are based on the molecular structure, complexity, dose, and duration of treatment with each drug.
Greed and the necessity for regulation (post)
On December 1, 2015, the U.S. Senate Finance Committee issued a scathing investigative report concluding that Gilead Sciences strategically priced its curative hepatitis C virus (HCV) treatments Sovaldi and Harvoni to yield an immediate financial windfall for the company, ignoring evidence and expert opinion that doing so would bust the budgets of public and private insurers and, consequently, prevent the medications from becoming available to all who need them. In February, Valeant Pharmaceuticals Limited and Turing Pharmaceuticals stood before members of the House Committee on Oversight and Government Reform, which conducted its own investigations into the sudden, inexplicable price increases for a number of lifesaving drugs. A month later, Turing executives were back on Capitol Hill, this time in front of irate members of the Senate Special Committee on Aging.
New Zealand’s PHARMAC to fund Sensipar; consult on Sirturo, Sylvant (post)
New Zealand’s Pharmaceutical Management Agency PHARMAC announced today (April 12) its decision to list cinacalcet (Sensipar) on the Pharmaceutical Schedule through an agreement with the local subsidiary of US biotech major Amgen (Nasdaq: ANGN) from May 1,2016 for:
Public health groups call for U.S. Congress to reject TPP (post)
More than 50 public health groups on Tuesday (April 12) called on Congress to reject a trade agreement between the United States and 11 other Pacific Rim nations because it will block access to affordable medicines.
Ideologies fly in discussion of WIPO pharma report calling for less ideology (post)
April 13, 2016 - A study commissioned by the World Intellectual Property Organization to analyse which essential medicines on the 2013 World Health Organization Essential Medicines List were under patent found that over 90 percent of medicines on the list were off patent, and advocated more transparency in patent information. The study’s release set off an outcry among public health advocates who viewed the report as biased toward pharmaceutical companies.
TB Alliance and the Medicines Patent Pool sign Memorandum of Understanding to improve access to TB medicines in resource-limited nations (post)
NEW YORK AND GENEVA (April 20, 2016) – TB Alliance and the Medicines Patent Pool (MPP) today announced a Memorandum of Understanding outlining a multi-pronged collaboration to encourage the development of new tuberculosis (TB) regimens and ensure their availability in low-and middle-income countries. The two organisations will work together on a range of initiatives, with a focus on public health-oriented licensing strategies and the sharing of intellectual property to spur research and development of affordable new TB treatments.
Page 20 of 83 · Total posts: 0
←First 19 20 21 Last→